Last updated: 2026-11-14 09:45:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
AstraZeneca PLC (AZN) operates in the -- sector and is listed on NYSE. The stock is currently priced at $184.49, with a market capitalization of $285.96B and a P/E ratio of 128.75. Over the past 52 weeks, its price has ranged from $153.41 to $212.71. This page covers its latest market performance, valuation, price trends and company information.
$285.96B | |
$184.77 | |
$186.13 | |
$183.96 | |
$184.38 | |
1.69M | |
3.04M | |
128.75 | |
$212.71 | |
$153.41 | |
1.24% | |
12-31 |
AstraZeneca PLC (AZN) last closed at $184.49 as of 2026-11-14 00:54:45, up 0.37% ($0.68) from the previous close of $184.38.
During the latest regular trading session, AZN traded between $183.96 and $186.13, with a volume of 1.69M shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, AstraZeneca PLC (AZN) moved from $186.85 to $184.49, representing a decline of 1.26% ($2.36).
The stock traded between $181.20 and $192.65 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 2.42 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 52.4%
AZN is currently trading at $184.49, placing it 52.4% of the way from its 52-week low of $153.41 to its 52-week high of $212.71. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
| Employees | 96,100 |
| CEO | Pascal Claude Roland Soriot |
| Founded | 1992 |
| Exchange | NYSE |
| Company Website |
View the latest dividend and stock split events for AstraZeneca PLC.
Dividend | |
|---|---|
| Ex-Dividend Date | Aug 7, 2026 |
| Payment Date | Sep 8, 2026 |
| Dividend Per Share | $0.795 |
Latest news related to AstraZeneca PLC and AZN stock.
https://news.cision.com/se/astrazeneca/r/baxfendy--baxdrostat--recommended-for-approval-in-the-eu-for-the-treatment-of-adults-with-hypertensi%2Cc4423959
DelveInsight released a comprehensive competitive landscape report on BCMA-targeted therapies, analyzing 100+ pipeline drugs across 80+ companies. The report highlights recent clinical advances including Pfizer's positive Phase III results for ELREXFIO, AbbVie's BLA submission for etentamig, and Gilead's $7.8 billion acquisition of Arcellx to gain control of anito-cel. Key challenges include treatment resistance, relapse, and manufacturing complexity, while the pipeline focuses on improving durability, safety, and accessibility through next-generation approaches.
DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.
Eligible investors can buy real shares of AstraZeneca PLC (AZN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Browse other US stocks in the same sector as AstraZeneca PLC
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to AZN, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between AZN shares and USD.
AZN Shares to USD
1.00 AZN shares = 184.494 USD
Calculations are estimates based on the latest available price and are for reference only.
